Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by waIlabe_shorton Oct 19, 2009 7:19am
792 Views
Post# 16399061

Amorfix accelerates warrant expiry

Amorfix accelerates warrant expiry

TORONTO, Oct. 19 /CNW/ -Amorfix Life Sciences, a company focused on treatments and diagnosticsfor misfolded protein diseases, announced today it will be acceleratingthe expiry of the warrants ("Warrants"), including the finders'warrants, that were issued on April 29, 2009 in connection with the closing of a private placement.

In accordance with the provisions of the Warrants, Amorfix mayshorten the expiry date of the Warrants if the volume-weighted averageprice of the common shares is $1.20 per share or higherover a period of ten consecutive trading days provided that it givesnotice of same in writing to the holders and the accelerated expirydate is a date which is not less than 30 calendar days after suchnotice is sent to the holders. The trigger for acceleration of theexpiry date was met on October 5, 2009 and Amorfixreports that it will be sending out notices to the holders of theWarrants advising them that the new expiry date shall be January 19, 2010.

If all of the remaining 2,597,795 warrants outstanding that aresubject to this accelerated expiry are exercised, Amorfix will receive $2,524,189of additional proceeds. Any warrants not exercised prior to theaccelerated expiry date will expire without any further action beingtaken.

Bullboard Posts